B
Blueprint Medicines Corp D
D
BPMC
104.720
USD
5.40
(5.44%)
مغلق
حجم التداول
73,249
الربح لكل سهم
-1
العائد الربحي
-
P/E
-98
حجم السوق
6,762,388,667
الأخبار المقالات
العنوان: Blueprint Medicines Corp
القطاع: Healthcare
الصناعة: Biotechnology
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patientsliving with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.